Indications -- Psoriasis/Chronic Inflammation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (286)	10/18/2002 8:18:33 AM
From: Icebrg	Read Replies (2) of 631

LFA-1 Antagonist (from Biogen's Q3 report) Biogen and ICOS Corporation are collaborating on the development of orally active, small molecule LFA-1 antagonists for the treatment of psoriasis and other autoimmune diseases. A Phase 2 trial in moderate-severe psoriasis to assess the safety, tolerability and pharmacokinetics of IC747, the lead molecule of the LFA-1 antagonist program, was initiated in the third quarter. LFA-1 is leukocyte function-associated antigen 1, a cell adhesion molecule that promotes T-cell migration and activation that can lead to inflammatory diseases like MS, psoriasis, rheumatoid arthritis and organ transplant rejection. LFA-1 antagonists block the molecule's action.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next